Spain's Highlight Has High Hopes For Immuno-Oncology Agent
Teamed Up With Merck & Co To Overcome PD1 Resistance
Executive Summary
After a decade of research, the Spanish biotech believes its lead candidate BO-112 can turn ‘cold’ tumors ‘hot,' offering the potential to rescue patients who are resistant to current checkpoint inhibitor therapy.
You may also be interested in...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.